BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 22, 2026
Home » Topics » Disease categories and therapies » Cancer

Cancer
Cancer RSS Feed RSS

Cancer

Chinese researchers patent new GTPase KRAS mutant inhibitors

Aug. 10, 2023
Guangzhou Lupeng Pharmaceutical Co. Ltd. and Newave Pharmaceutical LLC have divulged (mutant) ligands reported to be useful for the treatment of cancer, autoimmune disease and inflammation.
Read More
Cancer

Wigen Biomedicine Technology discovers HPK1 inhibitors

Aug. 10, 2023
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Shanghai Lisen Imprinting Pharmaceutical Technology describes new EGFR inhibitors for lung cancer

Aug. 10, 2023
Shanghai Lisen Imprinting Pharmaceutical Technology Co. Ltd. has disclosed EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of small-cell lung (SCLC) and l lung cancer (NSCLC).
Read More
Cancer

New PARP-1 inhibitors reported in Acerand Therapeutics patent

Aug. 10, 2023
Researchers from Acerand Therapeutics (Hong Kong) Ltd. have presented Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer, metabolic diseases, cardiovascular, inflammatory, psychiatric and immunological disorders.
Read More
Prostate cancer cells
Cancer

MC-1-F2 increases chemo-sensitivity of CRPC cell lines to docetaxel

Aug. 10, 2023
Researchers from the University of Texas System presented preclinical data for MC-1-F2, a direct small molecule inhibitor of forkhead box protein C2 (FOXC2). The candidate has previously shown activity in breast cancer cell lines, and the current study aimed to assess its efficacy in castration-resistant prostate cancer (CRPC).
Read More
Antibodies attacking cancer cell
Immuno-oncology

FDA clears Georgiamune’s IND application for GIM-122

Aug. 10, 2023
Georgiamune Inc. announced that the FDA cleared its IND application for GIM-122, a first-in-class dual-functioning monoclonal antibody designed to target a highly novel mechanism to overcome immunotherapy resistance.
Read More
Dotbio CEO Ignacio Asial with team
Newco news

Dotbio emerges with $5.6M pre-series A to advance multifunctional antibodies

Aug. 9, 2023
By Tamra Sami
Emerging from stealth mode, new immuno-oncology company Dotbio Pte. Ltd. closed an oversubscribed $5.6 million pre-series A round to accelerate development of its multifunctional and intracellular antibody therapies.
Read More
Photomicrograph of hepatocellular carcinoma

China approves world’s first methylation test for liver cancer

Aug. 9, 2023
By Doris Yu
Laboratory for Advanced Medicine & Health Group (LAMH)’s subsidiary Guangzhou Youze Biotechnology Co. Ltd. received marketing approval in China for its methylation test, which the company says is the first methylation test kit for liver cancer on the market in the world.
Read More
Cancer

Nanjing Zaiming Pharmaceutical presents new POLQ inhibitors

Aug. 9, 2023
Nanjing Zaiming Pharmaceutical Co. Ltd. has identified DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Regeneron Pharmaceuticals prepares and tests new HER2-targeting antibody-drug conjugate

Aug. 9, 2023
Regeneron Pharmaceuticals Inc. has disclosed an antibody-drug conjugate consisting of exatecan covalently linked to the antibody trastuzumab targeting HER2 through a linker reported to be useful for the treatment of cancer.
Read More
Previous 1 2 … 631 632 633 634 635 636 637 638 639 … 4139 4140 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • Alicorn synthesizes new AAK1 inhibitors

    BioWorld Science
    Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • Illustration of glucose in the blood stream

    CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

    BioWorld Science
    Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
  • Illustration of a child's brain

    Saniona reports preclinical data for SAN-2668

    BioWorld Science
    Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing